PA
CGBD icon

PharVision Advisers’s Carlyle Secured Lending CGBD Stock Holding History

PharVision Advisers’s Portfolio CGBD Stock Details CGBD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,041
Closed -$192K – 673
2025
Q2 		$192K Buy
+14,041
New +$200K 0.28% 210

Other funds holding CGBD

Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $8.15B AUM 20.12% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

PharVision Advisers's CGBD Position: Q3 2025 in Review

PharVision Advisers sold out of Carlyle Secured Lending (CGBD) in Q3 2025, closing a stake of 14,041 shares — an estimated $192K sold.

PharVision Advisers first reported a position in CGBD in Q2 2025 and held it in 1 quarter. The position peaked at $192K in Q2 2025. 149 funds tracked by Wall St. Rank hold CGBD as of Q3 2025.

  • PharVision Advisers reported no remaining Carlyle Secured Lending position as of Q3 2025 after selling out during the quarter.
  • PharVision Advisers sold 14,041 Carlyle Secured Lending shares in Q3 2025, an estimated $192K.
  • PharVision Advisers first reported a position in Carlyle Secured Lending in Q2 2025 and held it in 1 quarter.
  • PharVision Advisers's Carlyle Secured Lending position peaked at $192K in Q2 2025.
  • 149 funds tracked by Wall St. Rank held Carlyle Secured Lending as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.